Select Commercially Available Liquid Biopsy Assays

Liquid biopsies are beginning to fill a major niche in molecular diagnostics and the number of commercial companies offering liquid biopsy analysis is continuously increasing. Experts estimate that using DNA blood tests for cancer screening will be a $10-20 billion a year market by 2020. Companies are investing hundreds of millions of dollars to develop the innovative technologies required to test for liquid biopsies. Ultimately, a liquid biopsy may provide a less-expensive and less-invasive way to monitor patients throughout treatment, and large molecular diagnostic companies see this investment as high risk and even higher reward. As clinicians, it will be important to weigh the risks and benefits discussed earlier in this review, and compare and contrast the available liquid biopsy assays available. A non-inclusive list of commercially available liquid biopsy assays is listed here:

• Guardant360 (Guardant Health): http://www.guardanthealth.com/guardant360/
• FoundationACT^TM (Foundation Medicine): http://foundationone.com/docs/FoundationACT_AVWhitePaper.pdf
• Grail (Grail Bio, an Illumina spinoff): http://www.grailbio.com/
• Cobas EGFR Mutation Test v2 (Roche): http://egfrmutationtestv2.roche.com/liquid-biopsy
• Cancerintercept (Pathway Genomics): https://www.pathway.com/cancerintercept-liquid-biopsy/
• PlasmaSelect-R^TM (Personal Genome Diagnostics): http://www.personalgenome.com/research-services/liquid-biopsy/
• myRisk (Myriad Genetics): https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/
• Oncotype SEQ (Genomic Health): http://www.oncotypeseq.com/
• OncocEE (Biocept.com): http://biocept.com/

Thank you for participating in this module. Click below to download the certificate.